SwePub
Tyck till om SwePub Sök här!
Sök i LIBRIS databas

  Utökad sökning

WFRF:(Mourits Marian J E)
 

Sökning: WFRF:(Mourits Marian J E) > Nogues Catherine > Oral contraceptive ...

  • Schrijver, Lieske HNetherlands Cancer Institute (författare)

Oral contraceptive use and ovarian cancer risk for BRCA1/2 mutation carriers : an international cohort study

  • Artikel/kapitelEngelska2021

Förlag, utgivningsår, omfång ...

  • Elsevier BV,2021

Nummerbeteckningar

  • LIBRIS-ID:oai:lup.lub.lu.se:0c73d8cf-dff9-4139-a293-0f815a550bbb
  • https://lup.lub.lu.se/record/0c73d8cf-dff9-4139-a293-0f815a550bbbURI
  • https://doi.org/10.1016/j.ajog.2021.01.014DOI
  • http://kipublications.ki.se/Default.aspx?queryparsed=id:147144570URI

Kompletterande språkuppgifter

  • Språk:engelska
  • Sammanfattning på:engelska

Ingår i deldatabas

Klassifikation

  • Ämneskategori:art swepub-publicationtype
  • Ämneskategori:ref swepub-contenttype

Anmärkningar

  • BACKGROUND: Ovarian cancer risk in BRCA1 and BRCA2 mutation carriers has been shown to decrease with longer duration of oral contraceptive preparations (OCPs) use. While the effects of OCPs in the general population are well established (∼50% reduction), the estimated risk reduction in mutation carriers is much less precise due to potential bias and small sample sizes. In addition, only a few studies have examined the associations between duration of use, time since last use, starting age, and calendar year of start with risk of ovarian cancer.OBJECTIVE(S): To investigate in more detail the associations between various characteristics of OCP use and risk of ovarian cancer, to provide health care providers and carriers with better risk estimates.STUDY DESIGN: In this international retrospective study, ovarian cancer risk associations were assessed using OCP data on 3,989 BRCA1 and 2,445 BRCA2 mutation carriers. Age-dependent weighted Cox regression analyses were stratified by study and birth cohort and included breast cancer diagnosis as covariate. To minimize survival bias, analyses were left-truncated at 5 years before baseline questionnaire. Separate analysis were conducted for each of the aspects of OCP use and in a multivariate analysis including all these aspects. In addition, the analysis of duration of OCP use was stratified by recency of use.RESULTS: OCPs were less often used by mutation carriers who were diagnosed with ovarian cancer (Ever use: BRCA1 58.6%, BRCA2 53.5%) than by unaffected carriers (Ever use: BRCA1 88.9%, BRCA2 80.7%. The median duration of use was 7 years for both BRCA1 and BRCA2 carriers who developed ovarian cancer, and 9 and 8 years for ovarian cancer unaffected BRCA1 and BRCA2 carriers, respectively. For BRCA1 mutation carriers univariate analyses showed that both a longer duration of OCP use and more recent use of OCPs were inversely associated with risk of ovarian cancer. However, in multivariate analyses including duration of use, age at first use and time since last use, duration of use proved to be the prominent protective factor (compared with <5 years, 5-9 years HR=0.67;95%CI 0.40-1.12, 10+ years HR=0.37;95%CI 0.19-0.73; ptrend=0.008). The inverse association between duration of use and ovarian cancer risk persisted for more than 15 years (Duration of ≥10 years; BRCA1: <15 years since last use: HR=0.24 95%CI 0.14-0.43, 15+ years since last use: HR 0.56 95%CI 0.18-0.59). Univariate results for BRCA2 mutation carriers were similar, but due to limit sample size inconclusive.CONCLUSION: For BRCA1 mutation carriers, a longer duration of OCP use is associated with a greater reduction of ovarian cancer risk and the protection is long term.

Ämnesord och genrebeteckningar

Biuppslag (personer, institutioner, konferenser, titlar ...)

  • Antoniou, Antonis CUniversity of Cambridge (författare)
  • Olsson, HåkanSkåne University Hospital(Swepub:lu)onk-hol (författare)
  • Mooij, Thea MNetherlands Cancer Institute (författare)
  • Roos-Blom, Marie-JoséNetherlands Cancer Institute (författare)
  • Azarang, LeylaNetherlands Cancer Institute (författare)
  • Adlard, JulianChapel Allerton Hospital (författare)
  • Ahmed, MunazaGreat Ormond Street Hospital (författare)
  • Barrowdale, Daniel (författare)
  • Davidson, RosemarieQueen Elizabeth University Hospital, Glasgow (författare)
  • Donaldson, AlanSaint Michael's Hospital (författare)
  • Eeles, RosThe Institute of Cancer Research (författare)
  • Evans, D GarethManchester Metropolitan University (författare)
  • Frost, Debra (författare)
  • Henderson, AlexState Institute of Genetic and Regenerative Medicine, Kyiv (författare)
  • Izatt, LouiseCity of Hope National Medical Center (författare)
  • Ong, Kai-RenBirmingham Women’s Hospital Healthcare NHS Trust (författare)
  • Bonadona, ValérieClaude Bernard University Lyon 1 (författare)
  • Coupier, IsabelleArnaud de Villeneuve Hospital (författare)
  • Faivre, LaurenceGlobal Innovation Management Institute (GIMI) (författare)
  • Fricker, Jean-PierreCentre Paul Strauss (författare)
  • Gesta, PaulCentre Hospitalier Georges Renon (författare)
  • VAN Engelen, KlaartjeFox Chase Cancer Center (författare)
  • Jager, AgnesErasmus University Medical Center (författare)
  • Menko, Fred HNetherlands Cancer Institute (författare)
  • Mourits, Marian J EHanze University of Applied Sciences (författare)
  • Singer, Christian FMedical University of Vienna (författare)
  • Tan, Yen YMedical University of Vienna (författare)
  • Foretova, LenkaMasaryk Memorial Cancer Institute (författare)
  • Navratilova, MarieMasaryk Memorial Cancer Institute (författare)
  • Schmutzler, Rita K (författare)
  • Ellberg, CarolinaLund University,Lunds universitet,Tumörmikromiljö,Sektion I,Institutionen för kliniska vetenskaper, Lund,Medicinska fakulteten,LUCC: Lunds universitets cancercentrum,Övriga starka forskningsmiljöer,Biomarkörer och Epi,Institutionen för kliniska vetenskaper, Lund,Tumor microenvironment,Section I,Department of Clinical Sciences, Lund,Faculty of Medicine,LUCC: Lund University Cancer Centre,Other Strong Research Environments,Biomarkers and epidemiology,Department of Clinical Sciences, Lund(Swepub:lu)med-elc (författare)
  • Gerdes, Anne-MarieCopenhagen University Hospital: Juliane Marie Centre (författare)
  • Caldes, TrinidadHospital Clinico San Carlos de Madrid (författare)
  • Simard, JacquesCEA National Genotyping Center (CNG) (författare)
  • Olah, EdithNational Institute of Oncology, Budapest (författare)
  • Jakubowska, AnnaPomeranian Medical University (författare)
  • Rantala, JohannaKarolinska Institutet (författare)
  • Osorio, AnaSpanish National Cancer Research Center (CNIO) (författare)
  • Hopper, John LUniversity of Melbourne (författare)
  • Phillips, Kelly-AnneUniversity of Melbourne (författare)
  • Milne, Roger LUniversity of Melbourne (författare)
  • Terry, Mary BethUniversity of Northern British Columbia (författare)
  • NoguÈs, CatherineInstitut Paoli-Calmettes (författare)
  • Engel, ChristophUniversity Hospital Leipzig (författare)
  • Kast, Karin (författare)
  • Goldgar, David EUniversity of Utah (författare)
  • van Leeuwen, Flora ENetherlands Cancer Institute (författare)
  • Easton, Douglas F (författare)
  • Andrieu, NadinePSL University (författare)
  • Rookus, Matti ANetherlands Cancer Institute (författare)
  • Netherlands Cancer InstituteUniversity of Cambridge (creator_code:org_t)
  • EMBRACE Collaborators
  • GENEPSO Investigators
  • HEBON Investigators
  • IBCCS

Sammanhörande titlar

  • Ingår i:American Journal of Obstetrics and Gynecology: Elsevier BV225:1, s. 1-511097-68680002-9378

Internetlänk

Hitta via bibliotek

Till lärosätets databas

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy